---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024714"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T21:10:32.827047+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mesa Laboratories Reports First Quarter Fiscal 2026 Results

## Summary
- Total revenues increased 2.4% to $59,543,000 for the quarter ended June 30, 2025.
- Operating income decreased 45.1% to $3,064,000, impacted by FX and stock-based compensation.
- Clinical Genomics division revenue fell 10.7% core organic as China revenues contracted 69%.
- About $1.5M of expected Biopharmaceutical Development revenues shifted from Q1 to Q2 due to tariff surcharges.
- Non-GAAP adjusted operating income (excluding unusual items) was $12,902, down 15.9% year-over-year.

## SEC filing metadata
- accession: 0001437749-25-024714
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/0001437749-25-024714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774925024714/mlab20250804_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024714
- JSON: https://secwatch.observer/filing/0001437749-25-024714.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.